HZNP News and Press, Horizon Therapeutics Public Limited Company From 07/17/23

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be host...

2023-07-16 12:00:00 ET While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later this month, Barclays has picked Eli Lilly ( NYSE: LLY ) and Merck ( NYSE: MRK ) as two of the most favorably positioned ...

2023-07-16 07:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Mid cap stocks generat...

2023-07-14 15:00:24 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-07-13 15:16:45 ET Summary There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroid eye disease. Initiation of the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patient...

2023-07-13 11:05:34 ET Summary Merger arbitrage spreads are wide. A number of opportunities with spreads from 9% to 135%. Below you'll find a review of the most interesting setups in the merger arbitrage space. Merger arbitrage is an event-driven investment strategy focu...

2023-07-09 12:00:00 ET Despite a disappointing start to 2023, the healthcare sector has several promising industries waiting to outperform this year, Goldman Sachs said in a recent report after the bank concluded its annual healthcare conference in Dana Point, California, last month. Th...

2023-07-09 09:00:00 ET New U.S. guidelines proposed for regulators to review mergers and acquisitions have the potential to add months to a deal review, and companies and private equity firms may incur significant new costs. Last month, the Federal Trade Commission and the Department of...

-- Month 12 data reinforce durable efficacy of co-treatment approach -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA ® (pegloticase) injection with methotrexate, a...

-- Study shows subclinical spinal cord lesions were associated with future NMOSD attacks -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinic...